Enzo Biochem Gross Margin 2010-2022 | ENZ

Current and historical gross margin for Enzo Biochem (ENZ) over the last 10 years. The current gross profit margin for Enzo Biochem as of January 31, 2022 is %.
Enzo Biochem Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-01-31 $0.12B $0.05B 44.54%
2021-10-31 $0.12B $0.05B 45.69%
2021-07-31 $0.12B $0.05B 45.76%
2021-04-30 $0.11B $0.05B 46.02%
2021-01-31 $0.10B $0.04B 41.24%
2020-10-31 $0.09B $0.03B 35.29%
2020-07-31 $0.08B $0.02B 31.58%
2020-04-30 $0.08B $0.02B 28.57%
2020-01-31 $0.08B $0.02B 28.75%
2019-10-31 $0.08B $0.02B 27.50%
2019-07-31 $0.08B $0.02B 28.40%
2019-04-30 $0.08B $0.03B 30.12%
2019-01-31 $0.09B $0.03B 35.23%
2018-10-31 $0.10B $0.04B 38.95%
2018-07-31 $0.10B $0.04B 40.59%
2018-04-30 $0.10B $0.04B 41.75%
2018-01-31 $0.11B $0.04B 41.90%
2017-10-31 $0.11B $0.05B 42.86%
2017-07-31 $0.10B $0.05B 44.23%
2017-04-30 $0.11B $0.05B 45.28%
2017-01-31 $0.11B $0.05B 44.76%
2016-10-31 $0.10B $0.05B 44.23%
2016-07-31 $0.10B $0.05B 43.69%
2016-04-30 $0.10B $0.04B 43.14%
2016-01-31 $0.10B $0.04B 43.00%
2015-10-31 $0.10B $0.04B 42.86%
2015-07-31 $0.10B $0.04B 42.86%
2015-04-30 $0.10B $0.04B 43.30%
2015-01-31 $0.10B $0.04B 43.30%
2014-10-31 $0.10B $0.04B 43.30%
2014-07-31 $0.10B $0.04B 43.75%
2014-04-30 $0.09B $0.04B 42.55%
2014-01-31 $0.09B $0.04B 41.94%
2013-10-31 $0.09B $0.04B 41.30%
2013-07-31 $0.09B $0.04B 41.49%
2013-04-30 $0.10B $0.04B 43.30%
2013-01-31 $0.10B $0.05B 45.00%
2012-10-31 $0.10B $0.05B 46.60%
2012-07-31 $0.10B $0.05B 46.60%
2012-04-30 $0.10B $0.05B 46.15%
2012-01-31 $0.10B $0.05B 46.15%
2011-10-31 $0.10B $0.05B 44.66%
2011-07-31 $0.10B $0.05B 45.63%
2011-04-30 $0.10B $0.05B 44.55%
2011-01-31 $0.10B $0.04B 44.44%
2010-10-31 $0.10B $0.05B 45.92%
2010-07-31 $0.10B $0.05B 46.39%
2010-04-30 $0.10B $0.05B 47.42%
2010-01-31 $0.10B $0.05B 46.88%
2009-10-31 $0.09B $0.04B 44.68%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00